Connection
Kimberly Simmons to Hypoglycemic Agents
This is a "connection" page, showing publications Kimberly Simmons has written about Hypoglycemic Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.730 |
|
|
|
-
Karakus KE, Chesshir L, Walker S, Baschal EE, McDaniel KA, Triolo TM, Steck AK, Frohnert BI, Gottlieb PA, Michels AW, Simmons KM. Teplizumab treatment for stage 2 type 1 diabetes: a real-world evaluation of metabolic and immunological outcomes. Diabetologia. 2026 May; 69(5):1164-1175.
Score: 0.464
-
Simmons K, Michels AW. Lessons from type 1 diabetes for understanding natural history and prevention of autoimmune disease. Rheum Dis Clin North Am. 2014 Nov; 40(4):797-811.
Score: 0.211
-
Herold KC, Dayan CM, Chatenoud L, Gitelman SE, Sumnik Z, Simmons K, Szypowska A, Knecht LA, Niemoeller E, Rigby MR, Tian W, Hill R, Ramos EL. Preserving beta cell function in children and adolescents with newly diagnosed stage 3 type 1 diabetes: per-protocol population analysis from the PROTECT randomised trial. Diabetologia. 2026 Dec; 69(12):3501-3511.
Score: 0.030
-
Ramos EL, Dayan CM, Chatenoud L, Sumnik Z, Simmons KM, Szypowska A, Gitelman SE, Knecht LA, Niemoeller E, Tian W, Herold KC. Teplizumab and ß-Cell Function in Newly Diagnosed Type 1 Diabetes. N Engl J Med. 2023 12 07; 389(23):2151-2161.
Score: 0.025
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|